Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Regeneron Pharmaceuticals and Sanofi announced new analyses highlighting the efficacy of Dupixent® (dupilumab) in treating diseases driven by type 2 inflammation, including asthma, atopic dermatitis, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyposis. The results, to be presented at the AAAAI Virtual Annual Meeting from February 26 to March 1, demonstrate significant improvements in patients' symptoms across multiple studies. Dupixent, a fully-human monoclonal antibody, targets IL-4 and IL-13 signaling, vital in managing type 2 inflammatory diseases.
Regeneron Pharmaceuticals (NASDAQ: REGN) announced confirmation from Columbia University researchers that its REGEN-COV antibody cocktail neutralizes SARS-CoV-2 variants from the UK and South Africa. Published data indicates REGEN-COV retains effectiveness against these variants, with further studies ongoing for additional mutations. The cocktail features two monoclonal antibodies, imdevimab and casirivimab, designed to block virus infectivity. Regeneron is enhancing global supply through collaboration with Roche and is prepared to develop new antibody combinations to combat future variants.
Regeneron Pharmaceuticals reported positive initial results from a Phase 3 trial of REGEN-COV, an antibody cocktail for preventing COVID-19. The study showed a 100% prevention rate of symptomatic infections in high-risk individuals, and a 50% reduction in overall infections compared to placebo. Infections in the treatment group were asymptomatic with markedly lower viral loads and shorter durations of shedding. Safety assessments indicated fewer adverse events with REGEN-COV, and the injection method offers greater convenience. Full Phase 3 results are expected early Q2 2021.
Regeneron Pharmaceuticals and the Society for Science have announced the 2021 finalists for the Regeneron Science Talent Search, recognizing 40 exceptional high school seniors from a pool of 1,760 entrants. These finalists, selected for their scientific projects, will compete for over $1.8 million in awards during a virtual event March 10-17, 2021. Notable projects include studies on COVID-19 diagnostics and e-cigarette impacts on COPD. Each finalist will receive at least $25,000, with top prizes reaching $250,000.
On January 21, 2021, Regeneron Pharmaceuticals (NASDAQ: REGN) and the Society for Science announced the finalists for the Regeneron Science Talent Search 2021, highlighting 40 outstanding high school seniors selected from 1,760 entrants. They will compete for over $1.8 million in awards during a virtual competition from March 10-17, 2021. Finalists’ projects cover diverse STEM fields, addressing critical issues such as COVID-19 diagnostics and environmental concerns. Each finalist receives at least $25,000, with top awards reaching $250,000. This initiative fosters innovation and encourages young scientists.
Regeneron Pharmaceuticals (NASDAQ: REGN) will announce its fourth quarter and full year 2020 financial results on February 5, 2021, before U.S. markets open. A conference call will occur at 8:30 AM ET the same day, accessible by dialing (888) 660-6127 for U.S. callers or (973) 890-8355 for international participants, using conference ID 1580376. A webcast link will be available on their Investors and Media page. Regeneron is renowned for its innovations in biotechnology, focusing on treatments for serious diseases.
Regeneron Pharmaceuticals has announced a new agreement with the U.S. government to provide an additional 1.25 million doses of the casirivimab and imdevimab antibody cocktail, increasing the total potential supply to over 1.5 million doses. The antibody cocktail aims to treat high-risk patients with mild to moderate COVID-19 and is being supplied under FDA Emergency Use Authorization.
The government will purchase the doses at an estimated value of up to $2.625 billion, with 750,000 doses expected by June 30, 2021.
Regeneron Pharmaceuticals has revealed promising initial data from its Phase 1/2/3 trial of the antibody cocktail, casirivimab and imdevimab, for hospitalized COVID-19 patients. The data indicates a lower risk of death or mechanical ventilation in seronegative patients, achieving a hazard ratio of 0.78. These patients showed significant viral load reductions, with declines reaching -0.54 log10 copies/mL by day 7. While no serious adverse events were significant, the study emphasizes the impact of pre-existing immunity. The trial continues alongside the UK RECOVERY trial, with ongoing evaluations needed for conclusive results.
Regeneron Pharmaceuticals announced the publication of initial clinical data on its antibody cocktail, casirivimab and imdevimab, in the New England Journal of Medicine. This Phase 1/2/3 trial involved 275 patients and demonstrated significant reduction in viral load and need for medical visits in non-hospitalized COVID-19 patients. The treatment is available under Emergency Use Authorization, with follow-on data from 799 patients further validating its effectiveness, particularly in individuals without pre-existing antibodies.
Regeneron Pharmaceuticals (NASDAQ: REGN) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:20 a.m. ET. The presentation will be available for live streaming on their website. Regeneron is known for developing life-saving medications and has eight FDA-approved treatments. Their innovative drug development processes include proprietary technologies like VelociSuite and the Regeneron Genetics Center, contributing to their robust pipeline targeting serious health issues.